Limits...
Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.

Domnich A, Gasparini R, Amicizia D, Boccadifuoco G, Giuliani MM, Panatto D - J Immunol Res (2015)

Bottom Line: Existing laboratory techniques, such as multilocus sequence typing, are poorly suited to this purpose, since they do not provide information on the contribution of single vaccine components and therefore cannot be applied to estimate the potential coverage of the multicomponent vaccine.To date, MATS has proved advantageous for several reasons, including its ability to assess both qualitative and quantitative aspects of surface antigens of single strains in a highly reproducible, rapid, and resource-saving manner, while its shortcomings include a possible underestimation of 4CMenB coverage and the use of pooled sera to calculate the positive bactericidal threshold.This paper provides an overview of MATS development and its field application.

View Article: PubMed Central - PubMed

Affiliation: Department of Health Sciences, University of Genoa, Via Pastore 1, 16132 Genoa, Italy.

ABSTRACT
Development of the 4-component meningococcal serogroup B vaccine (4CMenB) has required new assays for the reliable evaluation of the expression and cross-reactivity of those specific antigen variants that are predicted to be targeted by bactericidal antibodies elicited by the vaccine in different isolates. Existing laboratory techniques, such as multilocus sequence typing, are poorly suited to this purpose, since they do not provide information on the contribution of single vaccine components and therefore cannot be applied to estimate the potential coverage of the multicomponent vaccine. The hSBA, the only correlate of protection against invasive meningococcal disease accepted thus far, cannot conveniently be used to test large number of strains. To overcome these issues, the meningococcal antigen typing system (MATS) has been specifically developed in order to predict 4CMenB coverage of individual meningococcus serogroup B strains. To date, MATS has proved advantageous for several reasons, including its ability to assess both qualitative and quantitative aspects of surface antigens of single strains in a highly reproducible, rapid, and resource-saving manner, while its shortcomings include a possible underestimation of 4CMenB coverage and the use of pooled sera to calculate the positive bactericidal threshold. This paper provides an overview of MATS development and its field application.

No MeSH data available.


Related in: MedlinePlus

4CMenB vaccine composition. Antigens NHBA and fHbp are fused with two accessory proteins, GNA1030 and GNA2091, respectively. Adapted with permission from [15].
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4553328&req=5

fig1: 4CMenB vaccine composition. Antigens NHBA and fHbp are fused with two accessory proteins, GNA1030 and GNA2091, respectively. Adapted with permission from [15].

Mentions: Neisseria meningitidis is a major causative agent of invasive bacterial diseases that affect mostly children between 3 and 12 months of age, followed by adolescents. Of thirteen known serogroups of N. meningitidis, only six (A, B, C, W-135, X, and Y) cause invasive disease [1, 2]. Active immunization is the most effective way to prevent invasive meningococcal disease; vaccines against serogroups A, C, W-135, and Y and a recently approved universal vaccine against serogroup B (MenB) are available [3]. This latter, a 4-component meningococcal serogroup B vaccine (4CMenB, commercially available as Bexsero), is the first vaccine to be developed by means of reverse vaccinology [4, 5]. 4CMenB consists of three recombinant proteins, namely, factor H binding protein (fHbp), Neisserial heparin-binding antigen (NHBA), and Neisseria adhesin A (NadA), combined with OMV from MenB strain NZ98/254, which contains porin A (PorA) serosubtype P1.4 (see Figure 1) [6].


Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.

Domnich A, Gasparini R, Amicizia D, Boccadifuoco G, Giuliani MM, Panatto D - J Immunol Res (2015)

4CMenB vaccine composition. Antigens NHBA and fHbp are fused with two accessory proteins, GNA1030 and GNA2091, respectively. Adapted with permission from [15].
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4553328&req=5

fig1: 4CMenB vaccine composition. Antigens NHBA and fHbp are fused with two accessory proteins, GNA1030 and GNA2091, respectively. Adapted with permission from [15].
Mentions: Neisseria meningitidis is a major causative agent of invasive bacterial diseases that affect mostly children between 3 and 12 months of age, followed by adolescents. Of thirteen known serogroups of N. meningitidis, only six (A, B, C, W-135, X, and Y) cause invasive disease [1, 2]. Active immunization is the most effective way to prevent invasive meningococcal disease; vaccines against serogroups A, C, W-135, and Y and a recently approved universal vaccine against serogroup B (MenB) are available [3]. This latter, a 4-component meningococcal serogroup B vaccine (4CMenB, commercially available as Bexsero), is the first vaccine to be developed by means of reverse vaccinology [4, 5]. 4CMenB consists of three recombinant proteins, namely, factor H binding protein (fHbp), Neisserial heparin-binding antigen (NHBA), and Neisseria adhesin A (NadA), combined with OMV from MenB strain NZ98/254, which contains porin A (PorA) serosubtype P1.4 (see Figure 1) [6].

Bottom Line: Existing laboratory techniques, such as multilocus sequence typing, are poorly suited to this purpose, since they do not provide information on the contribution of single vaccine components and therefore cannot be applied to estimate the potential coverage of the multicomponent vaccine.To date, MATS has proved advantageous for several reasons, including its ability to assess both qualitative and quantitative aspects of surface antigens of single strains in a highly reproducible, rapid, and resource-saving manner, while its shortcomings include a possible underestimation of 4CMenB coverage and the use of pooled sera to calculate the positive bactericidal threshold.This paper provides an overview of MATS development and its field application.

View Article: PubMed Central - PubMed

Affiliation: Department of Health Sciences, University of Genoa, Via Pastore 1, 16132 Genoa, Italy.

ABSTRACT
Development of the 4-component meningococcal serogroup B vaccine (4CMenB) has required new assays for the reliable evaluation of the expression and cross-reactivity of those specific antigen variants that are predicted to be targeted by bactericidal antibodies elicited by the vaccine in different isolates. Existing laboratory techniques, such as multilocus sequence typing, are poorly suited to this purpose, since they do not provide information on the contribution of single vaccine components and therefore cannot be applied to estimate the potential coverage of the multicomponent vaccine. The hSBA, the only correlate of protection against invasive meningococcal disease accepted thus far, cannot conveniently be used to test large number of strains. To overcome these issues, the meningococcal antigen typing system (MATS) has been specifically developed in order to predict 4CMenB coverage of individual meningococcus serogroup B strains. To date, MATS has proved advantageous for several reasons, including its ability to assess both qualitative and quantitative aspects of surface antigens of single strains in a highly reproducible, rapid, and resource-saving manner, while its shortcomings include a possible underestimation of 4CMenB coverage and the use of pooled sera to calculate the positive bactericidal threshold. This paper provides an overview of MATS development and its field application.

No MeSH data available.


Related in: MedlinePlus